| Byetta (exenatide) / AstraZeneca |
| Completed | N/A | 20 | | Exenatide injection and Metformin | The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, Fund from Suzhou Science & Technology Bureau (SYS201455)(SYS201534) | Diabetes mellitus | | | | |
ChiCTR-ONRC-14004356: Insulin pump intensive treatment combined with insulin and Byetta to reverse type 2 diabetes mellitus |
|
|
| Completed | N/A | 40 | | Insulin pump intensive treatment + insulin treatment for half a year ;Insulin pump intensive treatment for 2 weeks + insulin treatment for 6 months + 100% of the treatment for 6 months | Song County People's Hospital; Song County People's Hospital, from the technology bureau of Luoyang city and self-raised | type 2 diabetes mellitus | | | | |
ChiCTR-INR-16008242: Therapeutic effect of the Exenatide in the treatment of polycystic ovary syndrome |
|
|
| Not yet recruiting | N/A | 60 | | Exenatide+metformin ;metformin | Shengjing Hospital affiliated to China Medical University; shengjing hospital, self-financing | polycystic ovary syndrome | | | | |
| Completed | N/A | 20 | Europe | Ga-68-NODAGA-exendin-4 PET/CT | Radboud University Medical Center | Diabetes Mellitus, Type 2 | 04/24 | 04/24 | | |
ChiCTR2100047491: Bone morphogenetic protein-9 is involved in insulin resistance in polycystic ovary syndrome |
|
|
| Completed | N/A | 30 | | patients received interventional treatment with exenatide (EX) for 3 months. | Affiliated Hospital of Zunyi Medical University; Affiliated Hospital of Zunyi Medical University, Regional Science Foundation Project | Polycystic ovary syndrome | | | | |
GLP1R-T2D, NCT04733508: Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes |
|
|
| Recruiting | N/A | 28 | Europe | 111In-DTPA-exendin-4, IRDye800CW-exendin-4 | Radboud University, University of Coimbra | Diabetes Mellitus, Diabetes Mellitus, Type 2 | 06/22 | 12/22 | | |
| Completed | N/A | 26 | Europe | Saline 0.9%, Placebo, Glucagon (25ng/kg/min), Glucagon, Glucagon (50ng/kg/min), Exenatide | Cambridge University Hospitals NHS Foundation Trust | Cardiovascular Diseases | 11/21 | 11/21 | | |
ChiCTR2100045343: Bone morphogenetic protein-9 is involved in insulin resistance in polycystic ovary syndrome |
|
|
| Recruiting | N/A | 60 | | Exenatide intervention therapy ;None | Affiliated Hospital of Zunyi Medical University; Zunyi Medical University, Regional Science Foundation Project | Polycystic ovary syndrome | | | | |
| Active, not recruiting | N/A | 1400 | Europe | Byetta (Lilly, Exenatide), GLP-1 agonist, Conoxia (AGA, oxygen), Oxygen, 20% Human Albumin, Albumin | Rigshospitalet, Denmark | Coronary Disease, Shock, Cardiogenic, Renal Failure, Stroke, Brain Injury, Aortic Valve Disease | 01/24 | 01/24 | | |
NCT02244164: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. |
|
|
| Terminated | N/A | 5 | Europe | Incretinomimetics, - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®)., DPP-4 inhibitors, - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®). | Erasme University Hospital | Type 2 Diabetes, Incretinomimetics, Pancreas | 02/23 | 02/23 | | |
| Completed | N/A | 29 | Europe | Exenatide, Day 1 Exenatide; Day 2 : 0.9% saline solution, 0.9% saline solution, Day 1 : 0.9% saline solution, Day 2 Exenatide | University Hospital, Basel, Switzerland, Gottfried und Julia Bangerter-Rhyner-Stiftung | Endogenous Hyperinsulinism | 04/24 | 04/24 | | |
XYFY2023-KL479-01, NCT06256419: Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM |
|
|
| Recruiting | N/A | 300 | RoW | GLP-1 receptor agonist, responders group and nonresponders group | The Affiliated Hospital of Xuzhou Medical University | Type 2 Diabetes Mellitus, Susceptibility, Genetic | 01/28 | 01/28 | | |
| Recruiting | N/A | 270000 | US | SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA) | Kaiser Permanente, Geisinger Clinic, Henry Ford Health System, HealthPartners Institute, Patient-Centered Outcomes Research Institute | Type 2 Diabetes Mellitus, Cardiovascular Diseases | 06/24 | 08/25 | | |
CER-4-T2D, NCT05220917: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study |
|
|
| Active, not recruiting | N/A | 781430 | US | SGLT2 inhibitor, CANAGLIFLOZIN, CANAGLIFLOZIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE, DPP-4 inhibitor, ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL, SAXAGLIPTIN HCL/METFORMIN HCL, LINAGLIPTIN, LINAGLIPTIN/METFORMIN HCL, SITAGLIPTIN PHOSPHATE/METFORMIN HCL, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE/SIMVASTATIN, GLP-1RA, INSULIN DEGLUDEC/LIRAGLUTIDE*, INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG/LIXISENATIDE*, LIXISENATIDE, LIRAGLUTIDE, DULAGLUTIDE, SEMAGLUTIDE, ALBIGLUTIDE, EXENATIDE MICROSPHERES, EXENATIDE, 2nd generation SU, PIOGLITAZONE HCL/GLIMEPIRIDE, ROSIGLITAZONE MALEATE/GLIMEPIRIDE, GLIPIZIDE/METFORMIN HCL, GLYBURIDE,MICRONIZED, GLYBURIDE/METFORMIN HCL, GLIMEPIRIDE, GLYBURIDE, GLIPIZIDE | Brigham and Women's Hospital, Patient-Centered Outcomes Research Institute, VA Boston Healthcare System, McGill University | Cardiovascular Events, Type2 Diabetes, Renal Disease | 07/24 | 07/24 | | |
ChiCTR2300074467: The Comparative Study of [68Ga]-Exendin-4 and [68Ga]-DOTANOC PET/CT for Imaging of Insulinoma |
|
|
| Not yet recruiting | N/A | | | | Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, expenditure of department | Insulinoma | | | | |
